Concepedia

Lei Diao

LD

Statistics

Publications

3

Citations

39

H-Index

3

Active since

2022

Affiliations

Fosun Pharma (China)(Current)

Peking University Cancer Hospital

Peking University

Lei Diao is an author at Fosun Pharma (China) specializing in metastatic melanoma treatment, molecular oncology, and nras mutation.

ORCID

Publications per year

2022–2024

3

Publications

3

A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma

Lili Mao, Jun Guo, Lingjun Zhu et al. · European Journal of Cancer · 2022 · 17 citations

, , +15

Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas

Xiaojie Hu, Wenbin Li, Kang Zeng et al. · BMC Medicine · 2023 · 12 citations · Full text

, , +17

Population pharmacokinetic model for oral ORIN1001 in Chinese patients with advanced solid tumors

Xiaoqing Li, Yunhai Bo, Qingping Zeng et al. · Frontiers in Pharmacology · 2024 · 10 citations · Full text

, , +16

1–3 of 3